BioFunding

EC launches bioeconomy strategy

06.03.2012

A Brussels – The European Commission is boosting its investments and policy activities to foster sustainability. “Europe needs to make the transition to a post-petroleum economy,” said Máire Geoghegan-Quinn in Brussels. In mid-February, the Research Commissioner unveiled the bloc’s action plan for making the bioeconomy a reality by 2020. “We must drive the transition from a fossil-based to a bio-based society, with research and innovation as a motor,” she stated. “This is good for our environment, our food and energy security, and for Europe’s competitiveness for the future.”
The promise of a more efficient use of bio­degradable waste-streams and other bio­mass to produce foods, chemicals or energy is high, according to Commission estimates (see p. 3). Policymakers say by 2025 they expect a a10 return on each euro now being invested in EU-funded bio­economy research.
The action plan, entitled “Innovating for Sustainable Growth: a Bio­economy for Europe”, recommends boosting R&D investment and technology transfer as the most important priorities. The Commission intends to sink a4.7bn into bio­economy research within its Horizon2020 innovation programme (see EuroBiotechNews 11-12/2011), an investment that has been warmly welcomed by biotech industry stakeholders. “This is a milestone for Europe and the Europeans,” stressed industrial biotech expert Lars Hansen from the bio-industries association EuropaBio, who pointed to the need for additional “support of the member states to make the bioeconomy an EU success story.” Further money will be pumped in via national bioeconomy strategies that have been already been kicked-off in Germany, the Netherlands, Ireland, Finland and Denmark. Additionally, the Commission aims to create Private­Public Partnerships to trigger industry investments.
A second pillar in the agenda is improving the biomass value chain by boosting biomass production, establishing logistics to secure biomass supply and improving its conversion into value-added products in industrial-scale biorefineries. Additionally, the Commission announced it will support communication initiatives aimed at informing consumers about the benefits of bio-based products.

Measures remain vague

However, some industry representatives said they had hoped for more specific support from policymakers. “We had hoped for more concrete measures for bio­plastics to be integrated into the strategy,” said Andy Sweetman, head of European Bioplastics. “What we need are strong measures to support the market development of bio­plastics products.” Kaare Riis Nielsen, director for European affairs at Danish enzyme maker Novozymes, criticised the lack of clear action to support the adoption of second-generation biofuels made from lignocellulose. “Companies will go to the US and China if nothing happens in the policy environment. We need clear political leadership and long-term, stable market conditions,” he said.
According to the Commission, implementation of the bioeconomy in Europe will be dependent on getting all of the involved parties in one boat. Progress will be measured with the help of a newly established Bioeconomy Observatory and Bioeconomy Panel.

Politics / Law

06.03.2012

London – The European Medicines Agency (EMA) calls it “the biggest change to the legal framework since the establishment of the Agency in 1995.” This year, the EU drug regulators are preparing new so-called pharmacovigilance...

Clinical Trial

06.03.2012

Norway’s Algeta ASA (Oslo) has updated its Phase III survival analysis of Alpharadin in patients with castration-resistant prostate cancer and bone metastases. The analysis showed an increase of 3.6 months in median overall...

Clinical Trial

06.03.2012

Genticel S.A. (Toulouse) has completed enrolment in its Phase Ib study of a lyophilised version of the world’s very first therapeutic vaccine ProCervix, which inhibits infection with the cancer-causing Human Papilloma Virus. The...

Clinical Trial

06.03.2012

The share value of French specialist for cardiometabolic diseases Genfit S.A. (Loos/Lille) took a jump after the company announced its candidate drug GFT505 had met all efficacy endpoints in a pilot Phase II study involving 22...

Clinical Trial

06.03.2012

The US Food and Drug Administration (FDA) has granted a Biologics License Application (BLA) to the HER2 dimerisation inhibitor pertuzumab developed by Roche (Basel) for previously untreated HER2­-positive metastatic breast...

Politics / Law

06.03.2012

A For years, the world’s major patent offices – including the EPO, USPTO and JPO – have been collaborating in the Patent Prosecution Highway (PPH) programme. Under the PPH, an applicant whose claims have been allowed in one...

BioFunding

06.03.2012

Berlin/Dublin – Two EU initiatives are seeking to better predict response to cancer treatments. Researchers from the a6m RESPONSIFY Project will develop biomarker-based breast cancer prognosis tests that could be used to predict...

BioFunding

06.03.2012

Bremen/Brussels – European researchers kicked-off the MicroB3 (Bio­diversity, Bioinformatics, Biotechnology) project in February. Thanks to a a9m EU fund, the 32 groups involved will create a unique bioinformatic resource that...

Politics / Law

06.03.2012

Brussels – In February, I heard of a slightly mad and very worrying trend in decisions handed down by the Court of Justice of the European Union (CJEU) with regard to IP issues handed up from the national level for clarification....

Politics / Law

06.03.2012

The human race is at war with another species, and has been for thousands of years. Each of us in Europe swats dead dozens of the enemy every summer, and in the tropics they kill thousands of people with infectious diseases...

Displaying results 11 to 20 out of 1982

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/browse/1/article/ec-launches-bioeconomy-strategy.html

Product of the week

Products

Events

All Events

Current issue

All issues